On the cusp of a cure for COVID, one of the most promising yet under-the-radar biotech stocks on the OTC is generating much well-deserved buzz in...
One of the most exciting advances in biotechnology is the galectin inhibitor. Galectins are key proteins implicated in a wide range of chronic diseases. The leading...
Galectin Therapeutics (NASDAQ: GALT), Galecto Biotech (NASDAQ: GLTO), and BioXyTran Inc. (OTCMKTS: BIXT)—these three companies all currently have market capitalizations under $100 million in the field...
